UV Innovators was formed by
Todd Pope, Dr. Nick Medendorp, Jr.,
and Steve Grenon to develop a
medical-grade UVC handheld for hospitals to combat pathogens that cause hospital-acquired infections.
Together, they boast over 30 years of experience in medical science technology.
During the COVID-19 outbreak,
UV Innovators accelerated the development of its UVC disinfection solution to help businesses in need.
The company pivoted from its focus on hospital disinfection solutions to combat hospital-acquired infections (HAIs), to developing an industrial strength UVC handheld for industries that need powerful, portable and fast solutions.
UV Innovators is committed to providing the best UV germicidal technology to those that are on the front lines surface-clean services for a brighter and safer tomorrow.
Nick is a seasoned CEO, technology, and product development leader with more than 115 US patents in medical devices, electronic materials, LED and lighting products. Nick was an executive at Cree Lighting as it grew from $36k to ~$1B. Nick has 25+ years of experience commercializing photonic technology. He earned his BS, MS, and PhD in Materials Engineering from Purdue University.
Steve has a track record of consistently delivering innovations to market. He has more than 63 patents to his credit and more than 20 successful medical device product introductions. Most recently, he built and led the R&D team at Tear Science, which was acquired by Johnson and Johnson Surgical Vision in 2017. There he was promoted to the head of R&D for the Dry Eye Business Unit. He has a BS in Electrical Engineering from Northeastern University and graduate level course work from Stanford and Boston University.
Todd has successfully led medical device companies as CEO of TransEnterix, Johnson & Johnson Cordis and Liquidia Technologies, these range from start-ups, public companies to multi-billion-dollar revenue organizations. In 2018, Todd was named by Time magazine as one of the 50 most influential people in healthcare. Todd serves on the Board of Directors of AdvaMed ACCEL and the Educational Foundation for the University of North Carolina at Chapel Hill where he is the immediate past Executive Chairman of the Board.
Dr. David J. Weber is a world-renowned leader in the treatment of infectious diseases. He is the Charles Addison and Elizabeth Ann Sanders Distinguished Professor of Medicine and Pediatrics at the University of North Carolina (UNC) School of Medicine and Professor of Epidemiology in the UNC Gillings School of Global Public Health, Associate Chief Medical Officer for UNC Medical Center and serves as Medical Director, Department of Infection Prevention, UNC Medical Center. Dr. Weber is cited as an author in >440 scientific publications by PubMed.